INH for Prevention of TB — Still the Standard, But For How Long?

Data presented at AIDS 2012 demonstrated the efficacy of isoniazid among patients on ART but also highlighted the potential of weekly INH plus rifapentine.

Large controlled studies have confirmed that a 9-month course of daily or thrice-weekly isoniazid (INH) reduces the risk for tuberculosis (TB) in HIV-positive patients. However, those studies were conducted before the availability of potent antiretroviral therapy (ART).

At the 2012 International AIDS Conference, Molebogeng Rangaka presented data from a randomized trial of INH involving approximately 1300 HIV-infected patients who were starting or receiving ART in South Africa and did not have active TB [Abstract THLBB03]. The study participants were randomized to receive daily INH or matching placebo for 12 months. During 1 to 3 years of follow-up, those treated with ART + INH had a 37% lower rate of incident TB than those receiving ART alon…

Author

Helmut Albrecht, MD

Disclosures

Grant / Research supportHealth Resources and Services Administration; Centers for Disease Control and Prevention

Leadership positions in professional societiesColumbia Medical Society; South Carolina Infectious Diseases Society

Helmut Albrecht, MD

Disclosures

Grant / Research supportHealth Resources and Services Administration; Centers for Disease Control and Prevention

Leadership positions in professional societiesColumbia Medical Society; South Carolina Infectious Diseases Society

INH for Prevention of TB — Still the Standard, But For How Long?

Topics

Author